CA
ANIK icon

Clearstead Advisors’s Anika Therapeutics ANIK Stock Holding History

Clearstead Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542 Buy
+37
New +$548 ﹤0.01% 2900
2026
Q1 		– Sell
-2
Closed -$20 – 2275
2025
Q4 		$20 Sell
2
-30
-94% -$287 ﹤0.01% 2690
2025
Q3 		$301 Sell
32
-12
-27% -$115 ﹤0.01% 2805
2025
Q2 		$466 Buy
+44
New +$555 ﹤0.01% 2495

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IP
Indivisible Partners Clearwater, Florida $1.77B AUM
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Clearstead Advisors's ANIK Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Anika Therapeutics (ANIK) in Q2 2026: 37 shares worth $542. The stake represents ﹤0.01% of the portfolio and ranks #2900 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ANIK as recently as Q4 2025.

Clearstead Advisors first reported a position in ANIK in Q2 2025 and has held it in 4 quarters since. 43 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Clearstead Advisors held 37 shares of Anika Therapeutics worth $542 as of Q2 2026.
  • Anika Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Anika Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2900 holding.
  • Clearstead Advisors first reported a position in Anika Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 43 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.